External validation of the PUMA COPD diagnostic questionnaire in a general practice sample and the PLATINO study population
Received 21 February 2019
Accepted for publication 17 May 2019
Published 26 August 2019 Volume 2019:14 Pages 1901—1911
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Richard Russell
Maria Victorina Lopez Varela,1 Maria Montes de Oca,2 Fernando C Wehrmeister,3 Cecilia Rodriguez,1 Larissa Ramirez,4 Ana Menezes3
On behalf of the PLATINO team
1Department of Pulmonary, Universidad de la República, Montevideo, Uruguay; 2Department of Pulmonary, Universidad Central de Venezuela, Caracas, Venezuela; 3Department of Pulmonary, Federal University of Pelotas, Pelotas, Brazil; 4Department of Pulmonary, AstraZeneca, San Jose, Costa Rica
Correspondence: Maria Victorina Lopez Varela
Universidad de la República, Facultad de Medicina, Hospital Maciel, Montevideo 11200, Uruguay
Tel +598 9 961 7256
Background: A seven-item prescreening questionnaire (gender, age, pack-years smoking, dyspnea, sputum, cough, previous spirometry data) was developed for COPD detection in the primary care setting (PUMA Study) of four Latin America countries.
Objectives: To validate the PUMA prescreening COPD questionnaire externally in two different populations (primary care and general).
Methods: The PUMA prescreening COPD questionnaire score was applied to subjects from the Hospital Maciel, Montevideo (primary care), case-ﬁnding program and the PLATINO population (general) using PUMA study inclusion criteria. Post-bronchodilator FEV1/FVC <0.70 and lower limit of normal (LLN) criteria were used to define COPD. Area under the received operator curve (ROCAUC), sensitivity, specificity, predictive positive and negative values (PNV), number needed to treat (NNT), and best cut-points of the score were calculated.
Results: 974 individuals from Hospital Maciel and 2512 from the PLATINO population were eligible, using post-bronchodilator FEV1/FVC <0.70, 45.1% and 18.7% had COPD, respectively, and using LLN 38.4% and 15.4% had COPD, respectively. From Hospital Maciel (post-bronchodilator FEV1/FVC <0.70), the best cut-point of ≥6 had moderate discriminatory power (ROCAUC 0.70), sensitivity 69.9%, specificity 62.1%, PNV 70.9%, and NNT of 3. The discriminatory power was 0.73 (ROCAUC) in the PLATINO population with three potential cut-points (Youden’s index): ≥3 (sensitivity 85.4%, specificity 46.9%), ≥4 (sensitivity 66.7%, specificity 66.5%), and ≥5 (sensitivity 51.5%, specificity 81.6%); the PNV at each cut-point was 93.3%, 89.9%, and 88.0%, respectively. The NNT was 5 for scores ≥3 and ≥4, and 4 for ≥5. The mean accuracy using the LLN for Hospital Maciel and PLATINO was 0.67 and 0.70, respectively.
Conclusion: External validation of the PUMA prescreening questionnaire in two Latin American populations (general and primary care) suggests moderate accuracy, similar to the original study in which the questionnaire was developed.
Keywords: COPD, diagnostic questionnaire, primary care, validation, Latin America
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]